Thank you, Mr. Chair.
Actually, I would love to hear you continue, Dr. Marshall, with regard to how we sort out and monitor the progress that's been made for diagnosis and treatment, and then move on to the more long-term effects that Dr. Tator was talking about, the intensity of that kind of research.
Looking at it from the mandate of this committee—and we're not really clear on what is going to manifest itself from the testimony and the report and the recommendations—how can we be facilitating not just advances in research but also in the protocols that are needed and the standards and all of it?